Feasibility of 99m Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients
Standard
Feasibility of 99m Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients. / Köhler, Daniel; Sauer, Markus; Klutmann, Susanne; Apostolova, Ivayla; Lehnert, Wencke; Budäus, Lars; Knipper, Sophie; Maurer, Tobias.
In: J NUCL MED, Vol. 64, No. 1, 01.2023, p. 59-62.Research output: SCORING: Contribution to journal › Short publication › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Feasibility of 99m Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients
AU - Köhler, Daniel
AU - Sauer, Markus
AU - Klutmann, Susanne
AU - Apostolova, Ivayla
AU - Lehnert, Wencke
AU - Budäus, Lars
AU - Knipper, Sophie
AU - Maurer, Tobias
N1 - © 2023 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2023/1
Y1 - 2023/1
N2 - This case series evaluated the feasibility of prostate-specific membrane antigen (PSMA) radioguided surgery (RGS) with 99mTc-MIP-1404 in recurrent prostate cancer. Methods: 9 patients with PSMA-positive lesions on PET/CT received 99mTc-MIP-1404 (median 747 MBq, interquartile range (IQR) 710 - 764) 17.2 hours (IQR 16.9 - 17.5) before SPECT/CT and 22.3 hours (IQR 20.8 - 24.0) before RGS. Results: 17 PSMA-positive lesions were detected on PET/CT (median short axis diameter 4 mm, IQR 3 - 6; median SUVmax 8.9, IQR 5.2 - 12.6). 9/17 (52.9%) were visible on SPECT/CT (median SUVmax 13.8, IQR 8.0 - 17.9). Except for 2 foci, all PET/CT-positive findings demonstrated intraoperative count rates above the background (median counts 31, IQR 17 - 89) and were lymph node metastases. Moreover, PSMA-RGS identified 2 additional metastases compared to PET/CT. Prostate-specific antigen values decreased after RGS in 6/9 (67%) patients. Conclusion: PSMA-RGS with 99mTc-MIP-1404 identified lymph node metastases in all patients including two additional lesions compared to PET/CT.
AB - This case series evaluated the feasibility of prostate-specific membrane antigen (PSMA) radioguided surgery (RGS) with 99mTc-MIP-1404 in recurrent prostate cancer. Methods: 9 patients with PSMA-positive lesions on PET/CT received 99mTc-MIP-1404 (median 747 MBq, interquartile range (IQR) 710 - 764) 17.2 hours (IQR 16.9 - 17.5) before SPECT/CT and 22.3 hours (IQR 20.8 - 24.0) before RGS. Results: 17 PSMA-positive lesions were detected on PET/CT (median short axis diameter 4 mm, IQR 3 - 6; median SUVmax 8.9, IQR 5.2 - 12.6). 9/17 (52.9%) were visible on SPECT/CT (median SUVmax 13.8, IQR 8.0 - 17.9). Except for 2 foci, all PET/CT-positive findings demonstrated intraoperative count rates above the background (median counts 31, IQR 17 - 89) and were lymph node metastases. Moreover, PSMA-RGS identified 2 additional metastases compared to PET/CT. Prostate-specific antigen values decreased after RGS in 6/9 (67%) patients. Conclusion: PSMA-RGS with 99mTc-MIP-1404 identified lymph node metastases in all patients including two additional lesions compared to PET/CT.
KW - Male
KW - Humans
KW - Positron Emission Tomography Computed Tomography/methods
KW - Lymphatic Metastasis
KW - Feasibility Studies
KW - Neoplasm Recurrence, Local/diagnostic imaging
KW - Prostatic Neoplasms/diagnostic imaging
KW - Single Photon Emission Computed Tomography Computed Tomography
KW - Surgery, Computer-Assisted/methods
KW - Gallium Radioisotopes
U2 - 10.2967/jnumed.122.263892
DO - 10.2967/jnumed.122.263892
M3 - Short publication
C2 - 35835582
VL - 64
SP - 59
EP - 62
JO - J NUCL MED
JF - J NUCL MED
SN - 0161-5505
IS - 1
ER -
